Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.03
NYSE:HLS's Cash-to-Debt is ranked lower than
91% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 0.37 vs. NYSE:HLS: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:HLS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.07 Max: 1.11
Current: 0.03
0.01
1.11
Equity-to-Asset 0.23
NYSE:HLS's Equity-to-Asset is ranked lower than
85% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 0.50 vs. NYSE:HLS: 0.23 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:HLS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.25 Max: 0.69
Current: 0.23
-0.77
0.69
Debt-to-Equity 2.41
NYSE:HLS's Debt-to-Equity is ranked lower than
88% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 0.63 vs. NYSE:HLS: 2.41 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:HLS' s Debt-to-Equity Range Over the Past 10 Years
Min: -133.69  Med: 0.98 Max: 106.67
Current: 2.41
-133.69
106.67
Debt-to-EBITDA 3.26
NYSE:HLS's Debt-to-EBITDA is ranked lower than
53% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 2.82 vs. NYSE:HLS: 3.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:HLS' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.43  Med: 3.77 Max: 10.7
Current: 3.26
2.43
10.7
Interest Coverage 3.86
NYSE:HLS's Interest Coverage is ranked lower than
70% of the 224 Companies
in the Global Medical Care industry.

( Industry Median: 7.55 vs. NYSE:HLS: 3.86 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:HLS' s Interest Coverage Range Over the Past 10 Years
Min: 0.82  Med: 3.51 Max: 4.8
Current: 3.86
0.82
4.8
Piotroski F-Score: 5
Altman Z-Score: 1.60
Beneish M-Score: -2.77
WACC vs ROIC
3.03%
11.29%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.97
NYSE:HLS's Operating Margin % is ranked higher than
81% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. NYSE:HLS: 16.97 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:HLS' s Operating Margin % Range Over the Past 10 Years
Min: 10.83  Med: 18.53 Max: 22.19
Current: 16.97
10.83
22.19
Net Margin % 6.81
NYSE:HLS's Net Margin % is ranked higher than
66% of the 267 Companies
in the Global Medical Care industry.

( Industry Median: 4.16 vs. NYSE:HLS: 6.81 )
Ranked among companies with meaningful Net Margin % only.
NYSE:HLS' s Net Margin % Range Over the Past 10 Years
Min: 4.96  Med: 9.88 Max: 48.3
Current: 6.81
4.96
48.3
ROE % 31.93
NYSE:HLS's ROE % is ranked higher than
94% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 9.23 vs. NYSE:HLS: 31.93 )
Ranked among companies with meaningful ROE % only.
NYSE:HLS' s ROE % Range Over the Past 10 Years
Min: 31.93  Med: 62.72 Max: 1149.06
Current: 31.93
31.93
1149.06
ROA % 5.47
NYSE:HLS's ROA % is ranked higher than
64% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.45 vs. NYSE:HLS: 5.47 )
Ranked among companies with meaningful ROA % only.
NYSE:HLS' s ROA % Range Over the Past 10 Years
Min: 4.58  Med: 8.44 Max: 44.36
Current: 5.47
4.58
44.36
ROC (Joel Greenblatt) % 41.16
NYSE:HLS's ROC (Joel Greenblatt) % is ranked higher than
74% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 14.51 vs. NYSE:HLS: 41.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:HLS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 13.72  Med: 44.99 Max: 51.02
Current: 41.16
13.72
51.02
3-Year Revenue Growth Rate 18.50
NYSE:HLS's 3-Year Revenue Growth Rate is ranked higher than
83% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 7.70 vs. NYSE:HLS: 18.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:HLS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.2 Max: 18.5
Current: 18.5
0
18.5
3-Year EBITDA Growth Rate 12.80
NYSE:HLS's 3-Year EBITDA Growth Rate is ranked higher than
66% of the 186 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. NYSE:HLS: 12.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:HLS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -3.8 Max: 29.6
Current: 12.8
0
29.6
GuruFocus has detected 5 Warning Signs with Healthsouth Corp NYSE:HLS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:HLS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

HLS Guru Trades in Q3 2016

Joel Greenblatt 83,432 sh (+694.74%)
Paul Tudor Jones 14,184 sh (+40.02%)
Chuck Royce 183,713 sh (unchged)
Larry Robbins 7,169,780 sh (unchged)
Barrow, Hanley, Mewhinney & Strauss 1,693,950 sh (-0.59%)
Mariko Gordon 1,277,235 sh (-4.03%)
Columbia Wanger 3,178,922 sh (-8.16%)
Jim Simons 328,700 sh (-12.97%)
» More
Q4 2016

HLS Guru Trades in Q4 2016

Steven Cohen 1,400 sh (New)
John Hussman 2,400 sh (New)
Jim Simons 386,900 sh (+17.71%)
Mariko Gordon 1,408,590 sh (+10.28%)
Larry Robbins 7,269,780 sh (+1.39%)
Chuck Royce 183,713 sh (unchged)
Joel Greenblatt Sold Out
Barrow, Hanley, Mewhinney & Strauss 1,647,350 sh (-2.75%)
Columbia Wanger 2,810,846 sh (-11.58%)
Paul Tudor Jones 12,200 sh (-13.99%)
» More
Q1 2017

HLS Guru Trades in Q1 2017

Joel Greenblatt 67,205 sh (New)
John Hussman 102,400 sh (+4166.67%)
Jim Simons 710,200 sh (+83.56%)
Chuck Royce 183,713 sh (unchged)
Steven Cohen Sold Out
Larry Robbins Sold Out
Columbia Wanger 2,749,989 sh (-2.17%)
Mariko Gordon 1,373,403 sh (-2.50%)
Barrow, Hanley, Mewhinney & Strauss 1,571,956 sh (-4.58%)
Paul Tudor Jones 8,200 sh (-32.79%)
» More
Q2 2017

HLS Guru Trades in Q2 2017

David Dreman 748 sh (New)
John Hussman 152,400 sh (+48.83%)
Columbia Wanger 2,850,163 sh (+3.64%)
Chuck Royce 183,713 sh (unchged)
Paul Tudor Jones Sold Out
Barrow, Hanley, Mewhinney & Strauss 1,424,446 sh (-9.38%)
Mariko Gordon 1,202,135 sh (-12.47%)
Joel Greenblatt 34,300 sh (-48.96%)
Jim Simons 170,800 sh (-75.95%)
» More
» Details

Insider Trades

Latest Guru Trades with HLS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -9.38%0.01%$42.37 - $49.06 $ 46.000%1,424,446
Mariko Gordon 2017-06-30 Reduce -12.47%0.43%$42.37 - $49.06 $ 46.000%1,202,135
Joel Greenblatt 2017-06-30 Reduce -48.96%0.02%$42.37 - $49.06 $ 46.000%34,300
David Dreman 2017-06-30 New Buy0.02%$42.37 - $49.06 $ 46.000%748
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Reduce -4.58%$38.61 - $42.93 $ 46.0011%1,571,956
Mariko Gordon 2017-03-31 Reduce -2.50%0.08%$38.61 - $42.93 $ 46.0011%1,373,403
Joel Greenblatt 2017-03-31 New Buy0.04%$38.61 - $42.93 $ 46.0011%67,205
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -2.75%$38.34 - $42.35 $ 46.0013%1,647,350
Mariko Gordon 2016-12-31 Add 10.28%0.31%$38.34 - $42.35 $ 46.0013%1,408,590
Joel Greenblatt 2016-12-31 Sold Out 0.04%$38.34 - $42.35 $ 46.0013%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621498    SIC: 8093
Compare:BKK:BH, NAS:ACHC, NYSE:MD, NYSE:EVHC, SZSE:300015, NYSE:CHE, HAM:CLS1, XSGO:BANMEDICA, LSE:MDC, NYSE:SEM, JSE:NTC, ASX:HSO, NAS:LPNT, XTER:RHK, ISX:MIKA, NSE:APOLLOHOSP, SAU:4002, NYSE:AMN, JSE:LHC, ASX:SHL » details
Traded in other countries:HSOA.Germany,
Headquarter Location:USA
Healthsouth Corp provides post-acute healthcare services in the US through a network of inpatient rehabilitation hospitals, home health and hospice agencies. The firm operates in two segments: Inpatient Rehabilitation and Home Health and Hospice.

Healthsouth provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. The firm operates in two segments: inpatient rehabilitation and home health and hospice. The inpatient rehabilitation segment contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas. The home health and hospital segment provides skilled home health services through agencies concentrated in the southeastern United States and Texas, which include nursing, physical, occupational, and speech therapy, social work, and hospice services.

Ratios

vs
industry
vs
history
PE Ratio 16.85
HLS's PE Ratio is ranked higher than
76% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. HLS: 16.85 )
Ranked among companies with meaningful PE Ratio only.
HLS' s PE Ratio Range Over the Past 10 Years
Min: 1.71  Med: 13.87 Max: 29.71
Current: 16.85
1.71
29.71
Forward PE Ratio 15.72
HLS's Forward PE Ratio is ranked higher than
69% of the 58 Companies
in the Global Medical Care industry.

( Industry Median: 19.88 vs. HLS: 15.72 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.85
HLS's PE Ratio without NRI is ranked higher than
77% of the 196 Companies
in the Global Medical Care industry.

( Industry Median: 26.50 vs. HLS: 16.85 )
Ranked among companies with meaningful PE Ratio without NRI only.
HLS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.81  Med: 15.19 Max: 177.27
Current: 16.85
1.81
177.27
Price-to-Owner-Earnings 17.60
HLS's Price-to-Owner-Earnings is ranked higher than
70% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 26.22 vs. HLS: 17.60 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HLS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 2.42  Med: 13.78 Max: 52.94
Current: 17.6
2.42
52.94
PB Ratio 4.10
HLS's PB Ratio is ranked lower than
73% of the 251 Companies
in the Global Medical Care industry.

( Industry Median: 2.62 vs. HLS: 4.10 )
Ranked among companies with meaningful PB Ratio only.
HLS' s PB Ratio Range Over the Past 10 Years
Min: 3.81  Med: 7.61 Max: 189.01
Current: 4.1
3.81
189.01
PS Ratio 1.21
HLS's PS Ratio is ranked higher than
63% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 1.70 vs. HLS: 1.21 )
Ranked among companies with meaningful PS Ratio only.
HLS' s PS Ratio Range Over the Past 10 Years
Min: 0.4  Med: 1.14 Max: 1.91
Current: 1.21
0.4
1.91
Price-to-Free-Cash-Flow 11.70
HLS's Price-to-Free-Cash-Flow is ranked higher than
79% of the 124 Companies
in the Global Medical Care industry.

( Industry Median: 22.48 vs. HLS: 11.70 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HLS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.77  Med: 10.03 Max: 18.1
Current: 11.7
1.77
18.1
Price-to-Operating-Cash-Flow 7.44
HLS's Price-to-Operating-Cash-Flow is ranked higher than
80% of the 179 Companies
in the Global Medical Care industry.

( Industry Median: 14.62 vs. HLS: 7.44 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HLS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.53  Med: 6.75 Max: 11.6
Current: 7.44
1.53
11.6
EV-to-EBIT 11.52
HLS's EV-to-EBIT is ranked higher than
83% of the 209 Companies
in the Global Medical Care industry.

( Industry Median: 20.85 vs. HLS: 11.52 )
Ranked among companies with meaningful EV-to-EBIT only.
HLS' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.5  Med: 11.4 Max: 39.7
Current: 11.52
-25.5
39.7
EV-to-EBITDA 9.00
HLS's EV-to-EBITDA is ranked higher than
81% of the 227 Companies
in the Global Medical Care industry.

( Industry Median: 15.17 vs. HLS: 9.00 )
Ranked among companies with meaningful EV-to-EBITDA only.
HLS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.8  Med: 9.1 Max: 23.2
Current: 9
-43.8
23.2
EV-to-Revenue 1.95
HLS's EV-to-Revenue is ranked higher than
54% of the 265 Companies
in the Global Medical Care industry.

( Industry Median: 2.18 vs. HLS: 1.95 )
Ranked among companies with meaningful EV-to-Revenue only.
HLS' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 2.1 Max: 3.5
Current: 1.95
1.3
3.5
PEG Ratio 1.16
HLS's PEG Ratio is ranked higher than
83% of the 94 Companies
in the Global Medical Care industry.

( Industry Median: 3.00 vs. HLS: 1.16 )
Ranked among companies with meaningful PEG Ratio only.
HLS' s PEG Ratio Range Over the Past 10 Years
Min: 1.02  Med: 1.38 Max: 2.12
Current: 1.16
1.02
2.12
Shiller PE Ratio 14.62
HLS's Shiller PE Ratio is ranked higher than
91% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 27.79 vs. HLS: 14.62 )
Ranked among companies with meaningful Shiller PE Ratio only.
HLS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 11.43  Med: 15.73 Max: 264.4
Current: 14.62
11.43
264.4
Current Ratio 1.41
HLS's Current Ratio is ranked higher than
50% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.41 vs. HLS: 1.41 )
Ranked among companies with meaningful Current Ratio only.
HLS' s Current Ratio Range Over the Past 10 Years
Min: 0.6  Med: 2.14 Max: 10.68
Current: 1.41
0.6
10.68
Quick Ratio 1.41
HLS's Quick Ratio is ranked higher than
54% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.31 vs. HLS: 1.41 )
Ranked among companies with meaningful Quick Ratio only.
HLS' s Quick Ratio Range Over the Past 10 Years
Min: 0.6  Med: 1.94 Max: 10.68
Current: 1.41
0.6
10.68
Days Sales Outstanding 41.26
HLS's Days Sales Outstanding is ranked higher than
50% of the 220 Companies
in the Global Medical Care industry.

( Industry Median: 41.26 vs. HLS: 41.26 )
Ranked among companies with meaningful Days Sales Outstanding only.
HLS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.54  Med: 44.27 Max: 49.69
Current: 41.26
40.54
49.69

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.12
HLS's Dividend Yield % is ranked higher than
58% of the 250 Companies
in the Global Medical Care industry.

( Industry Median: 1.63 vs. HLS: 2.12 )
Ranked among companies with meaningful Dividend Yield % only.
HLS' s Dividend Yield % Range Over the Past 10 Years
Min: 0.5  Med: 2.03 Max: 2.83
Current: 2.12
0.5
2.83
Dividend Payout Ratio 0.35
HLS's Dividend Payout Ratio is ranked higher than
93% of the 151 Companies
in the Global Medical Care industry.

( Industry Median: 9999.00 vs. HLS: 0.35 )
Ranked among companies with meaningful Dividend Payout Ratio only.
HLS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.36 Max: 0.46
Current: 0.35
0.14
0.46
3-Year Dividend Growth Rate 37.70
HLS's 3-Year Dividend Growth Rate is ranked higher than
88% of the 82 Companies
in the Global Medical Care industry.

( Industry Median: 9.60 vs. HLS: 37.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
HLS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 37.7
Current: 37.7
0
37.7
Forward Dividend Yield % 2.21
HLS's Forward Dividend Yield % is ranked higher than
58% of the 240 Companies
in the Global Medical Care industry.

( Industry Median: 1.91 vs. HLS: 2.21 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 2.12
HLS's 5-Year Yield-on-Cost % is ranked lower than
53% of the 326 Companies
in the Global Medical Care industry.

( Industry Median: 2.24 vs. HLS: 2.12 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
HLS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.5  Med: 2.03 Max: 2.83
Current: 2.12
0.5
2.83
3-Year Average Share Buyback Ratio -0.40
HLS's 3-Year Average Share Buyback Ratio is ranked higher than
75% of the 159 Companies
in the Global Medical Care industry.

( Industry Median: -2.50 vs. HLS: -0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HLS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.5  Med: 1 Max: 0
Current: -0.4
-37.5
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.84
HLS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 103 Companies
in the Global Medical Care industry.

( Industry Median: 1.98 vs. HLS: 0.84 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HLS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.42  Med: 1.31 Max: 108.06
Current: 0.84
0.42
108.06
Price-to-Median-PS-Value 1.06
HLS's Price-to-Median-PS-Value is ranked lower than
53% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 1.03 vs. HLS: 1.06 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HLS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.42  Med: 1.1 Max: 3.42
Current: 1.06
0.42
3.42
Price-to-Peter-Lynch-Fair-Value 1.29
HLS's Price-to-Peter-Lynch-Fair-Value is ranked higher than
69% of the 55 Companies
in the Global Medical Care industry.

( Industry Median: 2.11 vs. HLS: 1.29 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
HLS' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.1  Med: 1.37 Max: 5.91
Current: 1.29
0.1
5.91
Earnings Yield (Greenblatt) % 8.70
HLS's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 269 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. HLS: 8.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HLS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4.2  Med: 8.6 Max: 15.8
Current: 8.7
-4.2
15.8
Forward Rate of Return (Yacktman) % 20.01
HLS's Forward Rate of Return (Yacktman) % is ranked higher than
78% of the 128 Companies
in the Global Medical Care industry.

( Industry Median: 8.93 vs. HLS: 20.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
HLS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3.2  Med: 17.3 Max: 26.7
Current: 20.01
3.2
26.7

More Statistics

Revenue (TTM) (Mil) $3,773.40
EPS (TTM) $ 2.73
Beta0.05
Short Percentage of Float6.04%
52-Week Range $36.97 - 49.71
Shares Outstanding (Mil)98.73

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,913 4,120 4,365
EPS ($) 2.70 2.89 3.18
EPS without NRI ($) 2.70 2.89 3.18
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($) 0.98 1.01 1.01

Piotroski F-Score Details

Piotroski F-Score: 55
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}